Replies to post #437209 on Anavex Life Sciences Corp (AVXL)

[raja48185]

The point I was making in my original post was more about the blatant declaration,(while dismissing any other opinion) that it would be approved by 2023 right after phase 2/3 was done.

There are other estimates too, like $6,000 pps based on assumptions like market penetration, market share etc.,SHOULD Blarcamesine get approved. Going a step further, if one had sold when it hit $25.00 plus and bought back when it hit $5.00 recently, then when the pps goes to 1249, once' should Blarcamesine get approved' happens, then it would be like hitting 1249x 5 =$ 6245 and that would be 100% profit, SHOULD one be able to offset all the gains with losses due to other stocks.

Let us get Rett Excellence data at least first and see how the pps reacts to the news and yes, I know, it will be released one day.

[scorman1]

therefore $1249 is reasonable target should Blarcamesine be approved and traditional valuation metrics used.

presuming the world stands still, which it doesn't....against the submarginal SOC, yes....against the two competitors who are finishing large AD phase 3 trials in 2024.....big NO !
competition is not standing still..... tempus fugit
We need clean, unambiguous Rett first, then let us see how the market responds